Compounds of formula (I) ##STR1## and the pharmaceutically acceptable base salts thereof, wherein R is --CO.sub.2 H or tetrazol-5 yl; R.sup.1 is C.sub.3 -C.sub.8 alkyl optionally substituted by fluoro; and R.sup.2 is C.sub.2 -C.sub.4 alkyl, together with compositions containing, uses of, process for the preparation of, and intermediates used in the preparation of, such compounds. The compounds have steroid 5.alpha.-reductase inhibitory activity and are useful for treating a disease such as benign prostatic hypertrophy.
                            化合物的公式(I) ##STR1##及其药用可接受的盐基,其中R为--CO.sub.2 H或
四唑-5-基;R.sup.1为C.sub.3-C.sub.8烷基,可选用
氟代基;R.sup.2为C.sub.2-C.sub.4烷基,还包括含有这种化合物、用途、制备过程以及制备中所使用的中间体的组合物。这些化合物具有类
固醇5α-还原酶抑制活性,并可用于治疗良性前列腺增生等疾病。